Loading...
Clinicians and menopausal women alike would welcome new agents that can prevent osteoporotic fractures with minimal adverse nonskeletal outcomes. In a manufacturer-sponsored international trial, investigators enrolled 8556 women (mean age, 67) who met bone-mineral density criteria for osteoporosis; participants received placebo or the investigational selective estrogen-receptor modulator (SERM) lasofoxifene (0.25 mg or 0.5 mg daily) for 5 years. The manufacturer is seeking FDA approval for this drug.
Women who received 0.5-mg lasofoxifene had substantially lower risk for vertebral (hazard ratio, 0.58) and nonvertebral (HR, 0.76) fractures than did women who received placebo. This dose of lasofoxifene was also associated with lower risk for e…